Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Feb;36(2):255–261. doi: 10.1128/aac.36.2.255

In vitro activity of sparfloxacin (AT-4140), a new quinolone agent, against invasive isolates from pediatric patients.

J C Akaniro 1, H R Stutman 1, A G Arguedas 1, O M Vargas 1
PMCID: PMC188342  PMID: 1318674

Abstract

Sparfloxacin is a new oral fluoroquinolone agent with putative activity against common pediatric pathogens. Using the broth microdilution method, we evaluated sparfloxacin activity in comparison with those of other antimicrobial agents against 383 pediatric isolates derived from cultures of blood and other normally sterile body fluids. MICs were assessed in Mueller-Hinton broth, serum, and urine, as well as at inoculum sizes of 10(4) to 10(8) CFU/ml. The emergence and stability of resistance and cross-resistance of Pseudomonas aeruginosa (mucoid and nonmucoid) and Staphylococcus aureus to sparfloxacin and ciprofloxacin were evaluated. Inhibitory activity of sparfloxacin against most test organisms was within achievable serum levels. Sparfloxacin was greater than or equal to 2- to 4-fold more active than other quinolones against gram-positive pathogens and 2- to 4-fold less active than ciprofloxacin against P. aeruginosa. Sparfloxacin activity was unaffected by urine and was enhanced by two- to eightfold in human serum. Its potency was not affected by inocula of less than or equal to 10(7) CFU/ml. The frequency of development of spontaneous resistance was similar to that found for other new quinolone agents, and stable resistance emerged only in P. aeruginosa. Sparfloxacin merits additional study against invasive pediatric pathogens.

Full text

PDF
255

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Akaniro J. C., Vidaurre C. E., Stutman H. R., Marks M. I. Comparative in vitro activity of a new quinolone, fleroxacin, against respiratory pathogens from patients with cystic fibrosis. Antimicrob Agents Chemother. 1990 Oct;34(10):1880–1884. doi: 10.1128/aac.34.10.1880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Barry A. L., Jones R. N. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid, norfloxacin, and oxolinic acid after in vitro selection of resistant populations. Antimicrob Agents Chemother. 1984 Jun;25(6):775–777. doi: 10.1128/aac.25.6.775. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cooper M. A., Andrews J. M., Ashby J. P., Matthews R. S., Wise R. In-vitro activity of sparfloxacin, a new quinolone antimicrobial agent. J Antimicrob Chemother. 1990 Nov;26(5):667–676. doi: 10.1093/jac/26.5.667. [DOI] [PubMed] [Google Scholar]
  4. Cozzarelli N. R. DNA gyrase and the supercoiling of DNA. Science. 1980 Feb 29;207(4434):953–960. doi: 10.1126/science.6243420. [DOI] [PubMed] [Google Scholar]
  5. Eliopoulos G. M., Klimm K., Grayson M. L. In vitro activity of sparfloxacin (AT-4140, CI-978, PD 131501), a new quinolone antimicrobial agent. Diagn Microbiol Infect Dis. 1990 Jul-Aug;13(4):345–348. doi: 10.1016/0732-8893(90)90029-u. [DOI] [PubMed] [Google Scholar]
  6. Jorgensen J. H., Redding J. S., Maher L. A., Howell A. W. Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol. 1987 Nov;25(11):2105–2113. doi: 10.1128/jcm.25.11.2105-2113.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against clinical bacterial isolates. Antimicrob Agents Chemother. 1989 Nov;33(11):1980–1988. doi: 10.1128/aac.33.11.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kojima T., Inoue M., Mitsuhashi S. In vitro activity of AT-4140 against quinolone- and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 1990 Jun;34(6):1123–1127. doi: 10.1128/aac.34.6.1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Nakamura S., Minami A., Nakata K., Kurobe N., Kouno K., Sakaguchi Y., Kashimoto S., Yoshida H., Kojima T., Ohue T. In vitro and in vivo antibacterial activities of AT-4140, a new broad-spectrum quinolone. Antimicrob Agents Chemother. 1989 Aug;33(8):1167–1173. doi: 10.1128/aac.33.8.1167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Piercy E. A., Barbaro D., Luby J. P., Mackowiak P. A. Ciprofloxacin for methicillin-resistant Staphylococcus aureus infections. Antimicrob Agents Chemother. 1989 Jan;33(1):128–130. doi: 10.1128/aac.33.1.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Raeburn J. A., Govan J. R., McCrae W. M., Greening A. P., Collier P. S., Hodson M. E., Goodchild M. C. Ciprofloxacin therapy in cystic fibrosis. J Antimicrob Chemother. 1987 Sep;20(3):295–296. doi: 10.1093/jac/20.3.295. [DOI] [PubMed] [Google Scholar]
  12. Sahm D. F., Koburov G. T. In vitro activities of quinolones against enterococci resistant to penicillin-aminoglycoside synergy. Antimicrob Agents Chemother. 1989 Jan;33(1):71–77. doi: 10.1128/aac.33.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Salam M. A., Bennish M. L. Therapy for shigellosis. I. Randomized, double-blind trial of nalidixic acid in childhood shigellosis. J Pediatr. 1988 Nov;113(5):901–907. doi: 10.1016/s0022-3476(88)80029-5. [DOI] [PubMed] [Google Scholar]
  14. Sanders C. C., Sanders W. E., Jr, Goering R. V. Overview of preclinical studies with ciprofloxacin. Am J Med. 1987 Apr 27;82(4A):2–11. [PubMed] [Google Scholar]
  15. Sanders C. C., Sanders W. E., Jr, Goering R. V., Werner V. Selection of multiple antibiotic resistance by quinolones, beta-lactams, and aminoglycosides with special reference to cross-resistance between unrelated drug classes. Antimicrob Agents Chemother. 1984 Dec;26(6):797–801. doi: 10.1128/aac.26.6.797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Schaad U. B., Wedgwood-Krucko J. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity. Infection. 1987 May-Jun;15(3):165–168. doi: 10.1007/BF01646040. [DOI] [PubMed] [Google Scholar]
  17. Scully B. E., Nakatomi M., Ores C., Davidson S., Neu H. C. Ciprofloxacin therapy in cystic fibrosis. Am J Med. 1987 Apr 27;82(4A):196–201. [PubMed] [Google Scholar]
  18. Stutman H. R., Akaniro J. C., Vidaurre C. E., Marks M. I. In vitro activity of E-1040, a 3-substituted cephalosporin, against pathogens from cystic fibrosis sputum. Antimicrob Agents Chemother. 1990 Jul;34(7):1366–1370. doi: 10.1128/aac.34.7.1366. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Tatsumi H., Senda H., Yatera S., Takemoto Y., Yamayoshi M., Ohnishi K. Toxicological studies on pipemidic acid. V. Effect on diarthrodial joints of experimental animals. J Toxicol Sci. 1978 Nov;3(4):357–367. doi: 10.2131/jts.3.357. [DOI] [PubMed] [Google Scholar]
  20. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Zweerink M. M., Edison A. Inhibition of Micrococcus luteus DNA gyrase by norfloxacin and 10 other quinolone carboxylic acids. Antimicrob Agents Chemother. 1986 Apr;29(4):598–601. doi: 10.1128/aac.29.4.598. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES